BioRestorative rises on recommendation to proceed mid-stage study of lead therapy

Biorestorative Therapies

07/07/2023 14:10

** Shares of cell therapy developer BioRestorative Therapies
Inc  BRTX.O  rise 4.1% premarket to $4.3
    ** Co says has received recommendation to proceed with its
mid-stage study for lead therapy BRTX-100
    ** Data Safety Monitoring Board, an independent review body,
which is overseeing dose and safety related issues during the
course of the trial approved the trial's continuation with no
changes to the current version of the protocol
    ** Adds there were no severe adverse events that were
correlated to dose limiting toxicity
     ** Co says will move ahead with the next stage of the
trial; will accelerate enrollment for the study
    ** BRTX-100 is being studied as a treatment for chronic
lumbar disc disease, which occurs when a disc in the low back
area of the spine bulges or herniates from between the bony area
of the spine
    ** Up to last close, stock up ~50% this year

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))